1. Immunology/Inflammation
  2. Interleukin Related
  3. Gevokizumab

Gevokizumab is a potent anti-IL-1β antibody, negatively modulates IL-1β signaling through an allosteric mechanism. Gevokizumab selectively decreases the binding affinity of IL-1β for the IL-1 receptor type I (IL-1RI) signaling receptor instead of IL-1 counter-regulatory decoy receptor (IL-1 receptor type II).

For research use only. We do not sell to patients.

Gevokizumab Chemical Structure

Gevokizumab Chemical Structure

CAS No. : 1129435-60-4

Size Price Stock Quantity
1 mg USD 220 In-stock
5 mg USD 550 In-stock
10 mg USD 880 In-stock
50 mg   Get quote  
100 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 1 publication(s) in Google Scholar

Top Publications Citing Use of Products
  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

Gevokizumab is a potent anti-IL-1β antibody, negatively modulates IL-1β signaling through an allosteric mechanism. Gevokizumab selectively decreases the binding affinity of IL-1β for the IL-1 receptor type I (IL-1RI) signaling receptor instead of IL-1 counter-regulatory decoy receptor (IL-1 receptor type II)[1][2].

In Vitro

Gevokizumab (5 nM; 16 h) shows inhibitory effects of IL-1β-mediated NF-kB activation caused by the soluble receptors, sIL-1RI and sIL-1RII in HeLa cells[1].
Gevokizumab (1.85, 5.55, 16.66, and 50 nM) is a selective negative allosteric modulator which reduces the binding affinity of sIL-1RI to IL-1β[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Gevokizumab (1 mg/kg; i.v.; once daily for 3 d) improves endothelial regrowth and reduces neointima formation in rats following carotid denudation[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Rat carotid denudation model in Sprague-Dawley rats (3-month0-old, 330-360 g)[2]
Dosage: 1, 10 and 50 mg/kg
Administration: Intravenous injection; once daily for 3 days
Result: Decreased carotid intima-media thickness (IMT) in the proximal part of the denuded artery at day 28, and improved endothelial regrowth at 1 mg/kg. 
Clinical Trial
CAS No.
Appearance

Liquid

Color

Colorless to light yellow

SMILES

[Gevokizumab]

Shipping

Shipping with dry ice.

Storage

Please store the product under the recommended conditions in the Certificate of Analysis.

Purity & Documentation

Purity: 98.12%

References
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

Gevokizumab Related Classifications

  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

 

Salutation

Applicant Name *

 

Email Address *

Phone Number *

 

Organization Name *

Department *

 

Requested quantity *

Country or Region *

     

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
Gevokizumab
Cat. No.:
HY-P99171
Quantity:
MCE Japan Authorized Agent: